Amplification and deletion of topoisomerase II associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

Research output: Contribution to journalArticleScientificpeer-review

375 Citations (Scopus)
Original languageEnglish
Pages (from-to)839-847
JournalAmerican Journal of Pathology
Volume156
Issue number3
DOIs
Publication statusPublished - 2000
Publication typeA1 Journal article-refereed

Cite this